COMP <GO>
ASMB vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Assembly Biosciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ASMB 1
— ABBV 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $20.86 (+1.41%) • MKT CAP: $424.7M
roic
-6.50%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASMB VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASMB | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -6.50% | 29.00% | -35.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.69% | 3.47% | -13.16 | ABBV | /fcf-yield <GO> |
| Operating Margin | -16.80% | 24.60% | -41.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.50% | 6.90% | -15.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 153.50% | 8.60% | +144.90 | ASMB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.57 | 5.33 | -3.76 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.9 | 65.1 | -29.24 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $424.7M | $513.86B | -$513.44B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASMB REV | ABBV REV | ASMB GROSS % | ABBV GROSS % | ASMB FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.3M | $61.16B | — | 70.2% | -$41.2M | $17.82B |
| FY 2024 | $28.5M | $56.33B | — | 70.0% | -$51.1M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | $22.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASMB // BETA —
ABBV // BETA 1.15